乙肝表面抗原水平停止与乙肝表面抗原阴性的慢性乙肝患者

StephenW

World J Gastroenterol. 2015 Jul 28;21(28):8653-8659.
Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients.Ge GH1, Ye Y1, Zhou XB1, Chen L1, He C1, Wen DF1, Tan YW1.
Author information

• 1Guo-Hong Ge, Yun Ye, Xin-Bei Zhou, Li Chen, Cong He, Dan-Feng Wen, You-Wen Tan, Department of Hepatosis, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212000, Jiangsu Province, China.
  

AbstractAIM: To investigate the virological relapse rate in hepatitis B e antigen (HBeAg)-negative patients after antiviral therapy discontinuation and analyze the factors associated with virological relapse.
METHODS: Among patients diagnosed with chronic hepatitis B infection between May 2005 and July 2010, 204 were eligible for analysis. The Kaplan-Meier method and log-rank test were used to calculate the cumulative rate of relapse and compare cumulative relapse rates between groups. The Cox proportional hazards regression model was used to evaluate the predictive factor of virological relapse.
RESULTS: The 2 and 1 year cumulative risks of virological relapse after antiviral therapy discontinuation were 79.41% (162/204) and 43.82% (71/162), respectively. Multivariate analysis revealed that only post treatment hepatitis B surface antigen (HBsAg) level was associated with virological relapse (P = 0.011). The cumulative risk of virological relapse was higher in the patients with HBsAg levels ≥ 1500 IU/L than in those with HBsAg levels < 1500 IU/L (P = 0.0013). The area under the curve was 0.603 (P = 0.033). The cutoff HBsAg value for predicting virological relapse was 1443 IU/L.
CONCLUSION: We found that the virological relapse rate remained high after antiviral therapy discontinuation in the HBeAg-negative patients and that the post treatment HBsAg levels predicted virological relapse.


KEYWORDS: Chronic hepatitis B; Hepatitis B surface antigen; Virological relapse

StephenW

世界ĴGastroenterol。 2015年07月28日; 21（28）：8653-8659。
乙肝表面抗原水平停止与乙肝表面抗原阴性的慢性乙肝患者的病毒学复发有关核苷（酸）类似物中。
葛GH1，叶Y1，周A2，陈L1，C1他，温家宝DF1，谭YW1。
作者信息

    1Guo宏戈叶云，心北周，李晨，丛河，丹奉文，你闻檀，肝病科，镇江江苏附属大学第三医院，镇江212000，江苏省，中国。

抽象
目的：

调查病毒学复发率乙型肝炎e抗原（HBeAg）阴性患者抗病毒治疗停药后，分析与病毒学复发有关的因素。
方法：

在患者诊断为慢性乙肝感染者2005年5月和2010年7月间，204例符合分析。在Kaplan-Meier法和log-rank检验用于计算复发率的累积和比较各组之间的累积复发率。 Cox比例风险回归模型被用来评估病毒学复发的预测因子。
结果：

病毒学复发的抗病毒治疗停药后的2和1年的累积风险分别为79.41％（204分之162）分别43.82％（162分之71）。多因素分析显示，只有治疗后乙肝表面抗原（HBsAg）水平与病毒学复发（P = 0.011）有关。病毒学复发的累积风险是在患者高于HBsAg水平≥1500 IU / L，比那些HBsAg水平<1500 IU / L（P = 0.0013）。曲线下面积为0.603（P = 0.033）。预测病毒学复发的乙肝表面抗原截止价值为1443 IU / L。
结论：

我们发现，病毒学复发率保持后的HBeAg阴性患者抗病毒治疗停药高，而且治疗后HBsAg水平预测病毒学复发。
关键词：

慢性乙型肝炎;乙型肝炎表面抗原;病毒学复发